1
|
Shadman M, Sharman JP, Levy MY, Porter R, Zafar SF, Burke JM, Chaudhry A, Freeman B, Misleh J, Yimer HA, Cultrera JL, Guthrie TH, Kingsley E, Rao SS, Chen DY, Zhang X, Idoine A, Cohen A, Feng S, Huang J, Flinn I. PRELIMINARY RESULTS OF THE PHASE 2 STUDY OF ZANUBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B‐CELL MALIGNANCIES INTOLERANT TO IBRUTINIB AND/OR ACALABRUTINIB. Hematol Oncol 2021. [DOI: 10.1002/hon.42_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Shadman
- Fred Hutchinson Cancer Research Center University of Washington Clinical Research Division Seattle, Washington USA
| | - J. P. Sharman
- Willamette Valley Cancer Institute and Research Center Clinical Research Division Eugene USA
| | - M. Y. Levy
- Texas Oncology‐Baylor Charles A. Sammons Cancer Center Hematology Dallas USA
| | - R. Porter
- SSM Health Dean Medical Group Hematology Madison USA
| | - S. F. Zafar
- Florida Cancer Specialists & Research Institute Oncology Fort Myers USA
| | - J. M. Burke
- Rocky Mountain Cancer Centers Oncology Aurora Colorado USA
| | | | - B. Freeman
- Summit Medical Group Oncology Florham Park USA
| | - J. Misleh
- Medical Oncology Hematology Consultants PA Hematology Newark USA
| | | | - J. L. Cultrera
- Florida Cancer Specialists & Research Institute Oncology Leesburg USA
| | | | - E. Kingsley
- Comprehensive Cancer Centers of Nevada Oncology Las Vegas USA
| | - S. S. Rao
- Alpha Med Physicians Group Oncology & Hematology Tinley Park USA
| | - D. Y. Chen
- BeiGene (Beijing) Co. Ltd. Beijing, China and BeiGene USA, Inc. Hematology San Mateo USA
| | - X. Zhang
- BeiGene (Beijing) Co. Ltd. Beijing, China and BeiGene USA, Inc. Hematology San Mateo USA
| | - A. Idoine
- BeiGene (Beijing) Co. Ltd. Beijing, China and BeiGene USA, Inc. Hematology San Mateo USA
| | - A. Cohen
- BeiGene (Beijing) Co. Ltd. Beijing, China and BeiGene USA, Inc. Hematology San Mateo USA
| | - S. Feng
- BeiGene (Beijing) Co. Ltd. Beijing, China and BeiGene USA, Inc. Hematology San Mateo USA
| | - J. Huang
- BeiGene (Beijing) Co. Ltd. Beijing, China and BeiGene USA, Inc. Hematology San Mateo USA
| | - I. Flinn
- Sarah Cannon Research Institute/Tennessee Oncology Oncology Nashville USA
| |
Collapse
|
2
|
Flinn I, Friedman JD, Ho L, Lee HJ. BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE IN NEWLY DIAGNOSED PATIENTS WITH ADVANCED HODGKIN LYMPHOMA (SGN35‐027, TRIAL IN PROGRESS). Hematol Oncol 2021. [DOI: 10.1002/hon.160_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- I. Flinn
- Sarah Cannon Research Institute and Tennessee Oncology Medical Oncology Nashville Tennessee USA
| | - J. D. Friedman
- University Hospitals Seidman Cancer Center Cleveland Ohio USA
| | - L. Ho
- Seagen Inc. Clinical Development Bothell Washington USA
| | - H. J. Lee
- MD Anderson Cancer Center Department of Lymphoma & Myeloma Houston Texas USA
| |
Collapse
|
3
|
Radford J, Connors J, Younes A, Gallamini A, Ansell S, Kim W, Cheong J, Flinn I, Kalakonda N, Kaminski M, Pettengell R, Onsum M, Josephson N, Kuroda S, Liu R, Miao H, Gautam A, Trepicchio W, Sureda A. EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON-1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC. Hematol Oncol 2019. [DOI: 10.1002/hon.99_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J. Radford
- Department of Medical Oncology; University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester United Kingdom
| | - J.M. Connors
- Centre for Lymphoid Cancer; British Columbia Cancer Centre for Lymphoid Cancer; Vancouver Canada
| | - A. Younes
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Gallamini
- Research; Innovation and Statistics Department, A Lacassagne Cancer Centre; Nice France
| | - S.M. Ansell
- Department of Medicine; Mayo Clinic; Rochester United States
| | - W.S. Kim
- Hematology-Oncology; Samsung Medical Center; Seoul Republic of Korea
| | - J. Cheong
- Division of Hematology; Department of Internal Medicine, Yonsei University College of Medicine; Seoul Republic of Korea
| | - I. Flinn
- Department of Oncology; Sarah Cannon Research Institute; Nashville United States
| | - N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - M. Kaminski
- Internal Medicine; University of Michigan; Ann Arbor United States
| | - R. Pettengell
- Haematology; St George's Hospital; London United Kingdom
| | - M. Onsum
- Biomarkers; Seattle Genetics, Inc.; Bothell United States
| | - N. Josephson
- Clinical Development; Seattle Genetics, Inc.; Bothell United States
| | - S. Kuroda
- Biostatistics; Takeda Development Center Japan, Takeda Pharmaceutical Company Limited; Osaka Japan
| | - R. Liu
- Biostatistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - H. Miao
- OTAU Clinical Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - A. Gautam
- Global Medical Affairs; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - W.L. Trepicchio
- Translational and Biomarker Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - A. Sureda
- Clinical Hematology; Institut Català d'Oncologia - Hospital Duran i Reynals; Barcelona Spain
| |
Collapse
|
4
|
Leonard J, Trneny M, Izutsu K, Fowler N, Hong X, Zhang H, Offner F, Scheliga A, Nowakowski G, Pinto A, Re F, Fogliatto L, Scheinberg P, Flinn I, Moreira C, Czuczman M, Kalambakas S, Fustier P, Wu C, Gribben J. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2
) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS. Hematol Oncol 2019. [DOI: 10.1002/hon.75_2629] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J. Leonard
- Meyer Cancer Center; Weill Cornell Medicine and New York Presbyterian Hospital; New York United States
| | - M. Trneny
- General Hospital; Charles University; Prague Czech Republic
| | - K. Izutsu
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - N. Fowler
- Department of Lymphoma and Myeloma; The University of Texas MD Anderson Cancer Center; Houston United States
| | - X. Hong
- Hematology; Fudan University Shanghai Cancer Center; Shanghai China
| | - H. Zhang
- Hematology; Tianjin Medical University Cancer Institute and Hospital; Tianjin China
| | | | - A. Scheliga
- Hematology; INCA Instituto Nacional De Câncer; Rio de Janeiro Brazil
| | - G. Nowakowski
- Division of Hematology; Department of Internal Medicine, Mayo Clinic; Rochester United States
| | - A. Pinto
- Hematology; Istituto Nazionale Tumori, Fondazione ‘G. Pascale’, IRCCS; Naples Italy
| | - F. Re
- Hematology; Azienda Ospedaliero-Universitaria di Parma; Parma Italy
| | - L. Fogliatto
- Hematology; Hospital de Clinicas de Porto Alegre; Porto Alegre Brazil
| | - P. Scheinberg
- Hematology; Hospital A Beneficência Portuguesa de São Paulo; São Paulo Brazil
| | - I. Flinn
- Hematology; Sarah Cannon Research Institute/Tennessee Oncology; Nashville United States
| | - C. Moreira
- Hematology; Instituto Português de Oncologia Do Porto Francisco Gentil Epe; Porto Portugal
| | - M. Czuczman
- Global Clinical R&D Hematology/Oncology; Celgene Corporation; Summit United States
| | - S. Kalambakas
- Global Medical Affairs; Celgene Corporation; Summit United States
| | - P. Fustier
- Global Medical Affairs; Celgene International Sarl; Boudry Switzerland
| | - C. Wu
- BioStatistics; Celgene Corporation; Summit United States
| | - J. Gribben
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| |
Collapse
|
5
|
Advani R, Bartlett N, Smith S, Roschewski M, Popplewell L, Flinn I, Collins G, Ghosh N, LaCasce A, Asch A, Kline J, Kesevan M, Tran T, Lynn J, Huang J, Agoram B, Volkmer J, Takimoto C, Chao M, Mehta A. THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS. Hematol Oncol 2019. [DOI: 10.1002/hon.57_2629] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- R. Advani
- Medicine; Stanford University; Stanford United States
| | - N.L. Bartlett
- Medicine; Washington University St. Louis; St, Louis United States
| | - S.M. Smith
- Medicine; University of Chicago; Chicago United States
| | - M. Roschewski
- Lymphoid Malignancies Branch; National Cancer Institute; Bethesda United States
| | - L. Popplewell
- Hematology/Oncology; City of Hope; Duarte United States
| | - I. Flinn
- Medicine; Sarah Cannon Research Institute; Nashville United States
| | - G. Collins
- Clinical Haematology; Oxford University; Oxford United Kingdom
| | - N. Ghosh
- Medicine; Atrium Health; Charlotte United States
| | - A. LaCasce
- Medicine; Dana Farber Cancer Institute; Boston United States
| | - A. Asch
- Hematology/Oncology; University of Oklahoma; Oklahoma City United States
| | - J. Kline
- Medicine; University of Chicago; Chicago United States
| | - M. Kesevan
- Clinical Haematology; Oxford University; Oxford United Kingdom
| | - T. Tran
- Medicine; Stanford University; Stanford United States
| | - J. Lynn
- Clinical Development; Forty Seven, Inc.; Menlo Park United States
| | - J. Huang
- Clinical Development; Forty Seven, Inc.; Menlo Park United States
| | - B. Agoram
- Clinical Development; Forty Seven, Inc.; Menlo Park United States
| | - J. Volkmer
- Clinical Development; Forty Seven, Inc.; Menlo Park United States
| | - C.H. Takimoto
- Clinical Development; Forty Seven, Inc.; Menlo Park United States
| | - M.P. Chao
- Clinical Development; Forty Seven, Inc.; Menlo Park United States
| | - A. Mehta
- Medicine; University of Alabama Birmingham; Birmingham United States
| |
Collapse
|
6
|
Barrientos J, Flinn I, Davids M, Cashen A, Chiorazzi N, Chen S, Hidy S, Pachter J, Lustgarten S, Weaver D, Brown J. PATTERNS OF DUVELISIB-INDUCED LYMPHOCYTOSIS IN PATIENTS WITH R/R CLL OR SLL INCLUDING THOSE WITH HIGH-RISK FACTORS TREATED IN THE DUO TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.31_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- J. Barrientos
- Department of Medicine; Zucker School of Medicine at Hofstra/Northwell; Lake Success NY United States
| | - I. Flinn
- Lymphoma Research; Sarah Cannon Research Institute/Tennessee Oncology; Nashville TN United States
| | - M.S. Davids
- Department of Medical Oncology; Dana-Farber Cancer Institute; Boston MA United States
| | - A. Cashen
- Division of Oncology; Washington University School of Medicine; St. Louis MO United States
| | - N. Chiorazzi
- Karches Center for Oncology Research; The Feinstein Institute for Medical Research; Manhasset NY United States
| | - S. Chen
- Karches Center for Oncology Research; The Feinstein Institute for Medical Research; Manhasset NY United States
| | - S. Hidy
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - J. Pachter
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - S. Lustgarten
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - D.T. Weaver
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - J. Brown
- Department of Medical Oncology; Dana-Farber Cancer Institute; Boston MA United States
| |
Collapse
|
7
|
Thieblemont C, Leonard J, Trneny M, Izutsu K, Fowler N, Hong X, Zhang H, Offner F, Scheliga A, Nowakowski G, Pinto A, Re F, Fogliatto L, Scheinberg P, Flinn I, Moreira C, Czuczman M, Kalambakas S, Fustier P, Wu C, Gribben J. POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R 2
) VS RITUXIMAB/PLACEBO (AUGMENT). Hematol Oncol 2019. [DOI: 10.1002/hon.41_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- C. Thieblemont
- Hemato-Oncology; APHP, Hopital Saint-Louis; Paris France
| | - J. Leonard
- Meyer Cancer Center; Weill Cornell Medicine and New York Presbyterian Hospital; New York United States
| | - M. Trneny
- General Hospital; Charles University; Prague Czech Republic
| | - K. Izutsu
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - N. Fowler
- Department of Lymphoma and Myeloma; The University of Texas MD Anderson Cancer Center; Houston United States
| | - X. Hong
- Hematology; Fudan University Shanghai Cancer Center; Shanghai China
| | - H. Zhang
- Hematology; Tianjin Medical University Cancer Institute and Hospital; Tianjin China
| | | | - A. Scheliga
- Hematology; INCA Instituto Nacional De Câncer; Rio de Janeiro Brazil
| | - G. Nowakowski
- Division of Hematology; Department of Internal Medicine, Mayo Clinic; Rochester United States
| | - A. Pinto
- Hematology; Istituto Nazionale Tumori, Fondazione ‘G. Pascale’, IRCCS; Naples Italy
| | - F. Re
- Hematology; Azienda Ospedaliero-Universitaria di Parma; Parma Italy
| | - L. Fogliatto
- Hematology; Hospital de Clinicas de Porto Alegre; Porto Alegre Brazil
| | - P. Scheinberg
- Hematology; Hospital A Beneficência Portuguesa de São Paulo; São Paulo Brazil
| | - I. Flinn
- Hematology; Sarah Cannon Research Institute/Tennessee Oncology; Nashville United States
| | - C. Moreira
- Hematology; Instituto Português de Oncologia Do Porto Francisco Gentil Epe; Porto Portugal
| | - M. Czuczman
- Global Clinical R&D Hematology/Oncology; Celgene Corporation; Summit United States
| | - S. Kalambakas
- Global Medical Affairs; Celgene Corporation; Summit United States
| | - P. Fustier
- Global Medical Affairs; Celgene International Sarl; Boudry Switzerland
| | - C. Wu
- BioStatistics; Celgene Corporation; Summit United States
| | - J. Gribben
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| |
Collapse
|
8
|
Barrientos J, Flinn I, Davids M, Cashen A, Chiorazzi N, Chen SS, Hidy S, Pachter J, Lustgarten S, Weaver D, Brown J. PS1160 PATTERNS OF DUVELISIB-INDUCED LYMPHOCYTOSIS IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA INCLUDING THOSE WITH HIGH-RISK FACTORS TREATED IN THE DUO TRIAL. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000562924.03733.7d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
9
|
Wang M, Belada D, Cheah C, Chu M, Dreyling M, Flinn I, Fogliatto L, Goy A, Inwards D, Jurczak W, Mayer J, Re F, Robak T, Spurgeon S, Yoon S, Zinzani P, Yin M, Chen T, Kahl B. A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT-NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- M. Wang
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston United States
| | - D. Belada
- Charles University Hospital and Faculty of Medicine; Fourth Department of Internal Medicine-Hematology; Hradec Králové Czech Republic
| | - C. Cheah
- Comprehensive Cancer Centre; Sir Charles Gairdner Hospital; Nedlands WA Australia
| | - M.P. Chu
- Clinician Scientist; Cross Cancer Institute; Edmonton Canada
| | - M. Dreyling
- Medizinische Klinik und Poliklinik III; Klinikum der Universität München, LMU München; München Germany
| | - I. Flinn
- Lymphoma Research; Sarah Cannon; Nashville United States
| | - L. Fogliatto
- Hematology; Irmandade da Santa Case de Misericórdia; Porto Alegre Brazil
| | - A. Goy
- Lymphoma Division; John Theurer Cancer Center, Hackensack University Medical Center; Hackensack United States
| | - D. Inwards
- Hematology; Mayo Clinic; Rochester United States
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Krakow Poland
| | - J. Mayer
- Hematology; Fakultní nemocnice Brno; Brno Czech Republic
| | - F. Re
- Hematology; Azienda Ospedaliero-Universitaria di Parma; Parma Italy
| | - T. Robak
- Hematology; Medical University of Lodz, Copernicus Memorial Hospital; Lodz Poland
| | - S. Spurgeon
- Hematology and Medical Oncology; OHSU Knight Cancer Institute; Portland United States
| | - S.S. Yoon
- Hemato Oncology; Seoul National University Hospital; Seoul Republic of Korea
| | - P.L. Zinzani
- Hematology; Institute of Hematology Seràgnoli, University of Bologna; Bologna Italy
| | - M. Yin
- Bio statistics; Acerta Pharma; South San Francisco United States
| | - T. Chen
- Clinical Development; Acerta Pharma; South San Francisco United States
| | | | | |
Collapse
|
10
|
Gribben J, Trneny M, Izutsu K, Fowler N, Hong X, Zhang H, Offner F, Scheliga A, Nowakowski G, Pinto A, Re F, Fogliatto L, Scheinberg P, Flinn I, Moreira C, Czuczman M, Kalambakas S, Fustier P, Wu C, Leonard J. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R 2
) THAN RITUXIMAB/PLACEBO. Hematol Oncol 2019. [DOI: 10.1002/hon.42_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J. Gribben
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| | - M. Trneny
- General Hospital; Charles University; Prague Czech Republic
| | - K. Izutsu
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - N.H. Fowler
- Department of Lymphoma and Myeloma; The University of Texas MD Anderson Cancer Center; Houston United States
| | - X. Hong
- Department of Medical Oncology; Fudan University Shanghai Cancer Center; Shanghai China
| | - H. Zhang
- Hematology; Tianjin Medical University Cancer Institute and Hospital; Tianjin China
| | | | - A. Scheliga
- Hematology; INCA Instituto Nacional De Câncer; Rio de Janeiro Brazil
| | - G. Nowakowski
- Division of Hematology; Department of Internal Medicine, Mayo Clinic; Rochester United States
| | - A. Pinto
- Hematology; Istituto Nazionale Tumori, Fondazione ‘G. Pascale’, IRCCS; Naples Italy
| | - F. Re
- Hematology; Azienda Ospedaliero-Universitaria di Parma; Parma Italy
| | - L. Fogliatto
- Hematology; Hospital de Clinicas de Porto Alegre; Porto Alegre Brazil
| | - P. Scheinberg
- Hematology; Hospital A Beneficência Portuguesa de São Paulo; São Paulo Brazil
| | - I. Flinn
- Hematology; Sarah Cannon Research Institute/Tennessee Oncology; Nashville United States
| | - C. Moreira
- Hematology; Instituto Português de Oncologia Do Porto Francisco Gentil Epe; Porto Portugal
| | - M. Czuczman
- Global Clinical R&D Hematology/Oncology; Celgene Corporation; Summit United States
| | - S. Kalambakas
- Global Medical Affairs; Celgene Corporation; Summit United States
| | - P. Fustier
- Global Medical Affairs; Celgene International Sarl; Boudry Switzerland
| | - C. Wu
- BioStatistics; Celgene Corporation; Summit United States
| | - J. Leonard
- Meyer Cancer Center; Weill Cornell Medicine and New York Presbyterian Hospital; New York United States
| |
Collapse
|
11
|
Sehn L, Assouline S, Bartlett N, Bosch F, Diefenbach C, Flinn I, Hong J, Kim W, Matasar M, Nastoupil L, Schuster S, Shadman M, Yoon S, Bender B, Chu W, Hernandez G, Kwan A, McCall B, Sison I, Wang C, Wei M, Yin S, Yousefi K, Budde L. MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP-UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL). Hematol Oncol 2019. [DOI: 10.1002/hon.119_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- L.H. Sehn
- Medical Oncology; BC Cancer Centre for Lymphoid Cancer and University of British Columbia; Vancouver BC Canada
| | - S. Assouline
- Division of Hematology; Jewish General Hospital; Montréal QC Canada
| | - N.L. Bartlett
- Siteman Cancer Center; Washington University School of Medicine; St. Louis MO United States
| | - F. Bosch
- Department of Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| | - C.M. Diefenbach
- Department of Hematology/Oncology; New York University Medical Center; Brooklyn NY United States
| | - I. Flinn
- Blood Cancer Research Program; Sarah Cannon Research Institute/Tennessee Oncology; Nashville TN United States
| | - J.Y. Hong
- Department of Oncology; ASAN Medical Center; Seoul Republic of Korea
| | - W.S. Kim
- Division of Hematology-Oncology; Department of Internal Medicine; Samsung Medical Center Seoul Republic of Korea
| | - M. Matasar
- Lymphoma Service; Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - L. Nastoupil
- Department of Lymphoma and Myeloma; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center; Houston TX United States
| | - S.J. Schuster
- Department of Medicine; Division of Hematology-Oncology, University of Pennsylvania; Philadelphia PA United States
| | - M. Shadman
- Medical Oncology Division; Department of Medicine, Fred Hutchinson Cancer Research Center; Seattle WA United States
| | - S.S. Yoon
- Division of Hematology/Medical Oncology; Department of Internal Medicine, Seoul National University Hospital; Seoul Republic of Korea
| | - B. Bender
- Clinical Pharmacology Development; Genentech, Inc.; South San Francisco CA United States
| | - W. Chu
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - G.M. Hernandez
- Oncology Biomarker Development; Genentech, Inc.; South San Francisco CA United States
| | - A. Kwan
- Safety Science Oncology; Genentech, Inc.; South San Francisco CA United States
| | - B. McCall
- Clinical Pharmacology Development; Genentech, Inc.; South San Francisco CA United States
| | - I. Sison
- Clinical Operations; gRED, Genentech, Inc.; South San Francisco CA United States
| | - C. Wang
- Safety Science Oncology; Genentech, Inc.; South San Francisco CA United States
| | - M.C. Wei
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - S. Yin
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - K. Yousefi
- Product Development; Biometrics, Biostatistics, Genentech, Inc.; South San Francisco CA United States
| | - L.E. Budde
- Department of Hematology and Hematopoietic Cell Transplantation; City of Hope Comprehensive Cancer Center; Duarte CA United States
| |
Collapse
|
12
|
Gribben J, Trneny M, Izutsu K, Fowler N, Hong X, Zhang H, Offner F, Scheliga A, Nowakowski G, Pinto A, Re F, Fogliatto L, Scheinberg P, Flinn I, Moreira C, Czuczman M, Kalambakas S, Fustier P, Wu C, Leonard J. PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT). Hemasphere 2019. [DOI: 10.1097/01.hs9.0000563288.81673.b1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
13
|
Harb W, Abramson J, Lunning M, Goy A, Maddocks K, Lebedinsky C, Senderowicz A, Trojer P, Bradley W, Flinn I. A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy048.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Blum K, Abramson J, Maris M, Flinn I, Goy A, Mertz J, Sims R, Garner F, Senderowicz A, Younes A. A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy048] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Flinn I, van der Jagt R, Chang J, Wood P, Hawkins T, MacDonald D, Trotman J, Simpson D, Kolibaba K, Issa S, Hallman D, Chen L, Burke J. FIRST-LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR OR R-CHOP/R-CVP: RESULTS OF THE BRIGHT 5-YEAR FOLLOW-UP STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_130] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- I. Flinn
- Medical Oncology; Sarah Cannon Research Institute; Nashville Tennessee USA
| | | | - J. Chang
- Department of Medicine, Hematology & Oncology; University of Wisconsin School of Medicine and Public Health, Madison; Wisconsin USA
| | - P. Wood
- Hematology, Division of Cancer Services; Princess Alexandra Hospital; Woolloongabba Queensland Australia
| | - T. Hawkins
- Haematology; Auckland City Hospital; Auckland New Zealand
| | - D. MacDonald
- Division of Hematology; Queen Elizabeth II Health Sciences Centre; Halifax Nova Scotia Canada
| | - J. Trotman
- Oncology, Clinical Research Unit; Concord Repatriation General Hospital; Concord New South Wales Australia
| | - D. Simpson
- Haematology; North Shore Hospital; Auckland New Zealand
| | - K. Kolibaba
- Oncology/Hematology; US Oncology Research, The Woodlands; Texas USA
| | - S. Issa
- Haematology; Middlemore Hospital; Auckland New Zealand
| | - D. Hallman
- Global Clinical Operations; Teva Pharmaceuticals; Malvern Pennsylvania USA
| | - L. Chen
- Biometrics Operations; Teva Pharmaceuticals; Malvern Pennsylvania USA
| | - J.M. Burke
- Oncology/Hematology; US Oncology Research, The Woodlands; Texas USA
| |
Collapse
|
16
|
Zinzani P, Wagner-Johnston N, Miller C, Ardeshna K, Tertreault S, Assouline S, Mayer J, Passamonti F, Lunin S, Pettitt A, Nagy Z, Tournilhac O, Abou-Nassar K, Crump M, Jacobsen E, De Vos S, Youssoufian H, Porter J, Prado S, Flinn I. DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_57] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- P. Zinzani
- Institute of Hematology Serágnoli; University of Bologna; Bologna Italy
| | | | - C. Miller
- Cancer Institute; St. Agnes Hospital; Baltimore USA
| | - K. Ardeshna
- Cancer Center; University College London; London UK
| | - S. Tertreault
- Department of Hematology; Florida Cancer Specialists Tallahassee; Tallahassee USA
| | - S. Assouline
- Division of Hematology; Jewish General Hospital; Montreal Canada
| | - J. Mayer
- Interni hematologicka; Onkologicka klinika-FN Brno; Brno Czech Republic
| | - F. Passamonti
- Oncology; Ospedale Di Circolo e Fondazione Macchi U.O. Ematologia; Varese Italy
| | - S. Lunin
- Hematology/Oncology; Florida Cancer Specialist Sarasotta; Sarasotta USA
| | - A. Pettitt
- Department of Molecular and Clinical Cancer Medicine, North West Cancer Research Centre; University of Liverpool; Liverpool UK
| | - Z. Nagy
- Belgyogyaszati Klinika; Semmelweis Egyetem, I. sz; Budapest Hungary
| | - O. Tournilhac
- Service d'hématologie; CHU Estaing; Clermont-Ferrand France
| | - K. Abou-Nassar
- Hematology; Centre intégré de santé et de services sociaux de l'Outaouais; Gatineau Canada
| | - M. Crump
- Hematology; Princess Margaret Cancer Center; Toronto Canada
| | - E. Jacobsen
- Hematology and Oncology; Beth Israel Deaconess Medical Center; Boston USA
| | - S. De Vos
- Hematology and Oncology; Ronald Reagan UCLA Medical Center; Los Angeles USA
| | | | - J. Porter
- Clinical Development; Verastem Inc.; Needham USA
| | - S. Prado
- Clinical Development; Verastem Inc.; Needham USA
| | - I. Flinn
- Hematology and Oncology; Sarah Cannon Research Institute; Nashville USA
| |
Collapse
|
17
|
Tam C, Quach H, Nicol A, Badoux X, Rose H, Prince H, Leahy M, Eek R, Wickham N, Patil S, Huang J, Zhang X, Wang L, Hedrick E, Novotny W, Flinn I. SAFETY AND ACTIVITY OF THE HIGHLY SPECIFIC BTK INHIBITOR, BGB-3111 PLUS OBINUTUZUMAB IN PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_102] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C.S. Tam
- Department of Haematology; St. Vincent's Hospital; East Melbourne Australia
| | - H. Quach
- Department of Haematology; St. Vincent's Hospital; East Melbourne Australia
| | - A. Nicol
- Lymphoma; Myeloma and Leukaemia, Brisbane Clinic; Brisbane Australia
| | - X. Badoux
- Haematology; St. George Hospital; Sydney Australia
| | - H. Rose
- Haematology; University Hospital; Geelong Australia
| | - H. Prince
- Haematology; St. Frances Xavier Cabrini Hospital; Malvern Australia
| | - M.F. Leahy
- Haematology; Royal Perth Hospital; Perth Australia
| | - R. Eek
- Research Unit; Border Medical Oncology; Albury Australia
| | - N. Wickham
- Ashford Cancer Centre Research; Adelaide Cancer Centre; Kurralta Park Australia
| | - S. Patil
- Haematology; The Alfred Hospital; Melbourne Australia
| | - J. Huang
- Research and Development Center, BeiGene, Beijing and Emeryville, CA; US China
| | - X. Zhang
- Research and Development Center, BeiGene, Beijing and Emeryville, CA; US China
| | - L. Wang
- Research and Development Center, BeiGene, Beijing and Emeryville, CA; US China
| | - E. Hedrick
- Research and Development Center, BeiGene, Beijing and Emeryville, CA; US China
| | - W. Novotny
- Research and Development Center, BeiGene, Beijing and Emeryville, CA; US China
| | - I. Flinn
- Center for Blood Cancers; Tennessee Oncology; Nashville USA
| |
Collapse
|
18
|
Tam C, Byrd J, O'Brien S, Coutre S, Barr P, Furman R, Kipps T, Burger J, Stevens D, Sharman J, Ghia P, Flinn I, Zhou C, Ninomoto J, James D, Wierda W. EFFECT OF SINGLE-AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). Hematol Oncol 2017. [DOI: 10.1002/hon.2438_96] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- C.S. Tam
- Department of Haematology; Peter MacCallum Cancer Centre and St. Vincent's Hospital; Melbourne Australia
| | - J.C. Byrd
- Division of Hematology, Department of Internal Medicine; The Ohio State University Medical Center; Columbus USA
| | - S. O'Brien
- Chao Family Comprehensive Cancer Center; University of California Irvine; Orange USA
| | - S. Coutre
- Division of Hematology, Stanford Cancer Center; Stanford University School of Medicine; Stanford USA
| | - P.M. Barr
- James P. Wilmot Cancer Center
- Department of Medicine, Hematology/Oncology, Wilmot Cancer Institute; University of Rochester Medical Center; Rochester USA
| | - R.R. Furman
- Division of Hematology and Medical Oncology; Weill Cornell Medical College; New York USA
| | - T.J. Kipps
- Department of Medicine; University of California San Diego, Moores Cancer Center; La Jolla USA
| | - J.A. Burger
- Department of Leukemia; University of Texas, MD Anderson Cancer Center, Houston; Houston USA
| | - D. Stevens
- Medical Oncology/Hematology; Norton Cancer Institute; Louisville USA
| | - J. Sharman
- US Oncology Research; Willamette Valley Cancer Institute & Research Center; Eugene USA
| | - P. Ghia
- Division of Molecular Oncology and Department of Onco-Hematology, Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele; Milan Italy
| | - I. Flinn
- Blood Cancer Research Program; Sarah Cannon Research Institute; Nashville USA
| | - C. Zhou
- Biometrics, Pharmacyclics LLC, an AbbVie Company; Sunnyvale USA
| | - J. Ninomoto
- Clinical Science, Pharmacyclics LLC, an AbbVie Company; Sunnyvale USA
| | - D.F. James
- Clinical Research, Pharmacyclics LLC, an AbbVie Company; Sunnyvale USA
| | - W.G. Wierda
- Department of Leukemia; University of Texas, MD Anderson Cancer Center, Houston; Houston USA
| |
Collapse
|
19
|
Neelapu S, Locke F, Bartlett N, Siddiqi T, Braunschweig I, Lekakis L, Goy A, Castro J, Oluwole O, Miklos D, Timmerman J, Jacobson C, Reagan P, Flinn I, Farooq U, Stiff P, Navale L, Elias M, Wiezorek J, Go W. ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.38] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia 2010; 24:1350-6. [PMID: 20508619 DOI: 10.1038/leu.2010.116] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
This phase 1 study (Clinicaltrials.gov: NCT00507442) was conducted to determine the maximum tolerated dose (MTD) of cyclophosphamide in combination with bortezomib, dexamethasone and lenalidomide (VDCR) and to assess the safety and efficacy of this combination in untreated multiple myeloma patients. Cohorts of three to six patients received a cyclophosphamide dosage of 100, 200, 300, 400 or 500 mg/m(2) (on days 1 and 8) plus bortezomib 1.3 mg/m(2) (on days 1, 4, 8 and 11), dexamethasone 40 mg (on days 1, 8 and 15) and lenalidomide 15 mg (on days 1-14), for eight 21-day induction cycles, followed by four 42-day maintenance cycles (bortezomib 1.3 mg/m(2), on days 1, 8, 15 and 22). The MTD was the cyclophosphamide dose below which more than one of six patients experienced a dose-limiting toxicity (DLT). Twenty-five patients were treated. Two DLTs were seen, of grade 4 febrile neutropenia (cyclophosphamide 400 mg/m(2)) and grade 4 herpes zoster despite anti-viral prophylaxis (cyclophosphamide 500 mg/m(2)). No cumulative hematological toxicity or thromboembolic episodes were reported. The overall response rate was 96%, including 20% stringent complete response (CR), 40% CR/near-complete response and 68% >or=very good partial response. VDCR is well tolerated and highly active in this population. No MTD was reached; the recommended phase 2 cyclophosphamide dose in VDCR is 500 mg/m(2), which was the highest dose tested.
Collapse
Affiliation(s)
- S K Kumar
- Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
He B, Wahl RL, Du Y, Sgouros G, Jacene H, Flinn I, Frey EC. Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--Monte Carlo simulation studies. IEEE Trans Med Imaging 2008; 27:521-30. [PMID: 18390348 PMCID: PMC2588667 DOI: 10.1109/tmi.2007.908131] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Estimating the residence times in tumor and normal organs is an essential part of treatment planning for radioimmunotherapy (RIT). This estimation is usually done using a conjugate view whole body scan time series and planar processing. This method has logistical and cost advantages compared to 3-D imaging methods such as Single photon emission computed tomography (SPECT), but, because it does not provide information about the 3-D distribution of activity, it is difficult to fully compensate for effects such as attenuation and background and overlapping activity. Incomplete compensation for these effects reduces the accuracy of the residence time estimates. In this work we compare residence times estimates obtained using planar methods to those from methods based on quantitative SPECT (QSPECT) reconstructions. We have previously developed QSPECT methods that provide compensation for attenuation, scatter, collimator-detector response, and partial volume effects. In this study we compared the use of residence time estimation methods using QSPECT to planar methods. The evaluation was done using the realistic NCAT phantom with organ time activities that model (111)In ibritumomab tiuxetan. Projection data were obtained using Monte Carlo simulations (MCS) that realistically model the image formation process including penetration and scatter in the collimator-detector system. These projection data were used to evaluate the accuracy of residence time estimation using a time series of QSPECT studies, a single QSPECT study combined with planar scans and the planar scans alone. The errors in the residence time estimates were 3.8%, 15%, and 2%-107% for the QSPECT, hybrid planar/QSPECT, and planar methods, respectively. The quantitative accuracy was worst for pure planar processing and best for pure QSPECT processing. Hybrid planar/QSPECT methods, where a single QSPECT study was combined with a series of planar scans, provided a large and statistically significant improvement in quantitative accuracy for most organs compared to the planar scans alone, even without sophisticated attention to background subtraction or thickness corrections in planar processing. These results indicate that hybrid planar/QSPECT methods are generally superior to pure planar methods and may be an acceptable alternative to performing a time series of QSPECT studies.
Collapse
Affiliation(s)
- B He
- Department of Radiology, The Johns Hopkins University, 601 North Caroline Street, Baltimore, MD 21287, USA.
| | | | | | | | | | | | | |
Collapse
|
22
|
Schilder RJ, Emmanouilides C, Vo K, Witzig TE, Flinn I, Darif M, Gordon L, Molina A. Yttrium 90 ibritumomab tiuxetan is safe and effective in older patients with relapsed or refractory NHL. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6562] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. J. Schilder
- Fox Chase Cancer Ctr, Philadelphia, PA; UCLA Medcl Ctr, Los Angeles, CA; Biogen Idec Inc, San Diego, CA; Mayo Clinic, Rochester, MN; John Hopkins Univ, Baltimore, MD; Northwestern Univ Medcl Sch, Chicago, IL
| | - C. Emmanouilides
- Fox Chase Cancer Ctr, Philadelphia, PA; UCLA Medcl Ctr, Los Angeles, CA; Biogen Idec Inc, San Diego, CA; Mayo Clinic, Rochester, MN; John Hopkins Univ, Baltimore, MD; Northwestern Univ Medcl Sch, Chicago, IL
| | - K. Vo
- Fox Chase Cancer Ctr, Philadelphia, PA; UCLA Medcl Ctr, Los Angeles, CA; Biogen Idec Inc, San Diego, CA; Mayo Clinic, Rochester, MN; John Hopkins Univ, Baltimore, MD; Northwestern Univ Medcl Sch, Chicago, IL
| | - T. E. Witzig
- Fox Chase Cancer Ctr, Philadelphia, PA; UCLA Medcl Ctr, Los Angeles, CA; Biogen Idec Inc, San Diego, CA; Mayo Clinic, Rochester, MN; John Hopkins Univ, Baltimore, MD; Northwestern Univ Medcl Sch, Chicago, IL
| | - I. Flinn
- Fox Chase Cancer Ctr, Philadelphia, PA; UCLA Medcl Ctr, Los Angeles, CA; Biogen Idec Inc, San Diego, CA; Mayo Clinic, Rochester, MN; John Hopkins Univ, Baltimore, MD; Northwestern Univ Medcl Sch, Chicago, IL
| | - M. Darif
- Fox Chase Cancer Ctr, Philadelphia, PA; UCLA Medcl Ctr, Los Angeles, CA; Biogen Idec Inc, San Diego, CA; Mayo Clinic, Rochester, MN; John Hopkins Univ, Baltimore, MD; Northwestern Univ Medcl Sch, Chicago, IL
| | - L. Gordon
- Fox Chase Cancer Ctr, Philadelphia, PA; UCLA Medcl Ctr, Los Angeles, CA; Biogen Idec Inc, San Diego, CA; Mayo Clinic, Rochester, MN; John Hopkins Univ, Baltimore, MD; Northwestern Univ Medcl Sch, Chicago, IL
| | - A. Molina
- Fox Chase Cancer Ctr, Philadelphia, PA; UCLA Medcl Ctr, Los Angeles, CA; Biogen Idec Inc, San Diego, CA; Mayo Clinic, Rochester, MN; John Hopkins Univ, Baltimore, MD; Northwestern Univ Medcl Sch, Chicago, IL
| |
Collapse
|
23
|
Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21:514-9. [PMID: 12560443 DOI: 10.1200/jco.2003.03.040] [Citation(s) in RCA: 157] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE The primary objective was to assess the duration of grade 4 neutropenia (neutrophil count < 0.5 x 10(9)/L) after one cycle of chemotherapy with etoposide, methylprednisolone, cisplatin, and cytarabine in patients randomly assigned to receive one dose of pegfilgrastim or daily filgrastim after chemotherapy. Febrile neutropenia, neutrophil profiles, time to neutrophil recovery, pharmacokinetics, and safety were also assessed. PATIENTS AND METHODS An open-label, randomized, phase II study was designed to compare the effects of a single subcutaneous injection of pegfilgrastim (sustained-duration filgrastim) 100 micro g/kg per chemotherapy cycle (n = 33) with daily subcutaneous injections of filgrastim 5 micro g/kg (n = 33) in patients receiving salvage chemotherapy for relapsed or refractory Hodgkin's or non-Hodgkin's lymphoma. RESULTS The incidence of grade 4 neutropenia in the pegfilgrastim and filgrastim groups was 69% and 68%, respectively. In addition, the mean duration of grade 4 neutropenia was similar in both groups (2.8 and 2.4 days, respectively). The results for the two groups were also not significantly different for febrile neutropenia, neutrophil profile, time to neutrophil recovery, or toxicity profile. A single subcutaneous injection of pegfilgrastim 100 micro g/kg produced a sustained serum concentration relative to daily subcutaneous injections of filgrastim. Filgrastim-treated patients received a median of 11 injections per cycle. CONCLUSION Pegfilgrastim was safe and well tolerated in this patient population. A single injection of pegfilgrastim per chemotherapy cycle provided neutrophil support with safety and efficacy similar to that provided by daily injections of filgrastim. Once-per-cycle administration of pegfilgrastim simplifies the management of neutropenia and may have important clinical benefits for patients and healthcare providers.
Collapse
Affiliation(s)
- J M Vose
- University of Nebraska Medical Center, Omaha, NE 68198, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Noga SJ, Vogelsang GB, Miller SC, Meusel S, Loper K, Case R, Myers B, Rogers L, Flinn I, Borowitz M, O'Donnell P. Using point-of-care CD34 enumeration to optimize PBSC collection conditions. Cytotherapy 2003; 3:11-8. [PMID: 12028839 DOI: 10.1080/146532401753156368] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
BACKGROUND A PBSC graft containing 4-5 x 10(6) CD34(+) cells/kg is considered optimal in terms of durable engraftment. Tracking CD34 kinetics via point-of-care testing during PBSC mobilization could determine which (and when) patients will yield an optimal product. We evaluated whether microvolume fluorimetry (MVF) would be useful in optimizing PBSC mobilization/harvest and if it will shorten our standard 6 h collection. METHODS Absolute CD34 values were obtained using the IMAGN 2000 and STELLer CD34 assay (50 microL sample volume). Peripheral blood (PB) CD34 values from 30 patients undergoing PBSC mobilization were used to generate a PB CD34-based algorithm that would predict collection day/duration of apheresis. The algorithm was then used prospectively to collect PBSC products on 50 hematologic malignancy (HM) patients. RESULTS Using the algorithm, patients were assigned to either a 6 (11-20 CD34/microL), 4 (21-49 CD34/microL) or 2 (> or = 50 CD34/microL) h collection. Patients with a CD34 value < or = 10/microL were re-tested. All patients (n = 43) predicted to mobilize reached the optimal CD34 (4-5 x 10(6)/kg) value with 1.0 apheresis procedure; seven patients had < or = 10/microL (nonmobilizers). The majority (75%) had apheresis charges decreased by 33-66%; 47% only required a 2 h procedure and 28% required 4 h. All patients demonstrated rapid trilineage engraftment. DISCUSSION Absolute PB CD34 measurement using MVF offers a rapid and reliable approach to obtaining optimal PBSC products with minimal technical expertise. Although not a replacement for conventional flow cytometry, it meets the requirements for a point-of-care procedure.
Collapse
Affiliation(s)
- S J Noga
- The Johns Hopkins Hematopoietic and Therapeutic Support Service, Baltimore, MD 21205, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
|
26
|
Noga S, O'Donnell P, Flinn I, Loper K, Meusal S, Vogelsang G. Do mobilization kinetics differ among hematological malignancies (Hm) When priming and collection methods are optimized? Exp Hematol 2000. [DOI: 10.1016/s0301-472x(00)00380-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
27
|
O'Donnell PV, Jones RJ, Vogelsang GB, Seber A, Ambinder RF, Flinn I, Miller C, Marcellus DC, Griffin C, Abrams R, Braine HG, Grever M, Hess AD, Piantadosi S, Noga SJ. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies. Bone Marrow Transplant 1998; 22:947-55. [PMID: 9849691 DOI: 10.1038/sj.bmt.1701476] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Although T cell depletion of allografts used in BMT has reduced GVHD, it has been associated with inferior engraftment and an increased risk of relapse. We have found that T cell depletion by counterflow centrifugal elutriation (CCE) also results in depletion of CD34+ stem cells. In order to determine if the discarded CD34+ cells would improve engraftment, we undertook a phase II trial of allogeneic BMT in which 110 patients (median age 43) with a variety of hematologic malignancies received CD34+ stem cell augmented, elutriated marrow grafts. The T cell-depleted grafts were tightly controlled and contained a mean of 4.3 x 10(7) mononuclear cells/kg, 3.3 x 10(6) CD34+ cells/kg, 1.5 x 10(5) CFU-GM/kg and 5.5 x 10(5) CD3+ T cells/kg. Median time to engraftment of granulocytes (>500/microl) was 16 days and of platelets (>50000/microl) was 25 days, comparable to that seen with unmanipulated marrow. No mixed hematopoietic chimerism was observed that was not associated with disease relapse. The four patients (3.6%) who failed to engraft were all at high risk because of prior donor transfusions or underlying marrow disorders. The incidence of GVHD was dependent on the duration of cyclosporin A (CsA) immunosuppression. In patients who received CsA for > or = 80 days, the incidence of clinically significant acute GVHD (>stage 1) and extensive, chronic GVHD was 5% and 11%, respectively. Peritransplant (< or = 100 day post-BMT) mortality for this group of patients was 15%. Event-free survival in selected subsets of patients compared favorably to previous studies in which patients received unmanipulated marrow allografts.
Collapse
Affiliation(s)
- P V O'Donnell
- The Johns Hopkins Oncology Center, Baltimore, MD 21287, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
|